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Discovery and structural characterization of a 
therapeutic antibody against coxsackievirus A10
Rui Zhu1*, Longfa Xu1*, Qingbing Zheng1*, Yanxiang Cui2,3*, Shaowei Li1*, Maozhou He1,  
Zhichao Yin1, Dongxiao Liu1, Shuxuan Li1, Zizhen Li1, Zhenqin Chen1, Hai Yu1, Yuqiong Que1,  
Che Liu1, Zhibo Kong1, Jun Zhang1, Timothy S. Baker4, Xiaodong Yan1,4†, Z. Hong Zhou2,3†,  
Tong Cheng1†, Ningshao Xia1†
Coxsackievirus A10 (CVA10) recently emerged as a major pathogen of hand, foot, and mouth disease and herpangina 
in children worldwide, and lack of a vaccine or a cure against CVA10 infections has made therapeutic antibody 
identification a public health priority. By targeting a local isolate, CVA10-FJ-01, we obtained a potent antibody, 
2G8, against all three capsid forms of CVA10. We show that 2G8 exhibited both 100% preventive and 100% ther-
apeutic efficacy against CVA10 infection in mice. Comparisons of the near-atomic cryo–electron microscopy struc-
tures of the three forms of CVA10 capsid and their complexes with 2G8 Fab reveal that a single Fab binds a border 
region across the three capsid proteins (VP1 to VP3) and explain 2G8’s remarkable cross-reactivities against all 
three capsid forms. The atomic structures of this first neutralizing antibody of CVA10 should inform strategies for 
designing vaccines and therapeutics against CVA10 infections.
INTRODUCTION
Coxsackievirus A10 (CVA10), a member of the enterovirus spe-
cies A (EV-A; family Picornaviridae), has become one of the major 
causative agents of hand, foot, and mouth disease (HFMD) and 
herpangina (HA) in children worldwide (1). Outbreaks of HFMD/
HA associated with CVA10 recently occurred in Asia (2–5), Africa (6), 
and Europe (7–9). For example, a local outbreak was recorded in the 
Fujian Province of China as recently as 2014, which led to the isola-
tion of the CVA10-FJ-01 strain used in this study. CVA10 infections 
can lead to typical clinical symptoms of HFMD as well, and some 
serious complications such as onychomadeses (9, 10), hyperCKemia 
(11), convulsion (12), central nervous system disorders (12, 13), and 
even death (14). Furthermore, HFMD surveillance data confirmed 
the upward trend in its cocirculation with other enteroviruses, such 
as enterovirus 71 (EV71), CVA16, and CVA6, which have caused 
more severe clinical outcomes (9). Although CVA10 has reemerged 
as a considerable global public health threat, no cure or vaccine is 
yet available.
CVA10 belongs to the Picornaviridae, a large family of nonen-
veloped, small (~30 nm in diameter), plus-strand RNA viruses with 
an icosahedral capsid (1). An effective therapeutic approach is 
to develop neutralizing antibodies (NAbs), as has been demonstrated 
for influenza A virus (15) and Zika virus (16). The atomic structures 
of virus-NAb complexes allow the identification of viral epitopes, 
which are critical for rational vaccine development and for under-
standing mechanisms of virus neutralization (17–19). However, such 
an approach has yet to be explored for CVA10. It is well known that 
picornaviruses generally undergo several steps of structural tran-
sition during assembly and infection: procapsid, mature virion, 
A-particle, and empty particle (20–23). Neutralization can occur at 
multiple steps during infection at different phases of viral entry and 
spread (24). NAbs have been shown to promote untimely uncoating 
of the virus and premature genome release in picornavirus EV71 
and human rhinovirus (HRV) (19, 25). Because of the lack of know-
ledge about the existence of, and similarities/differences among, the 
multiple capsid forms of CVA10, whether NAbs can cross-react 
with different forms of particles, or influence transitions between 
them, is unknown.
Here, we report the immunological and structural characteriza-
tions of the isolated CVA10 procapsid, A-particle, and mature virion, 
each of which has the potential to be an ideal vaccine candidate, 
particularly the mature virion because it has the strongest antigen-
icity. Furthermore, we have also identified and characterized a 
CVA10-specific NAb, named 2G8, we demonstrate not only its 
high binding efficiency and potent neutralization activity but also 
strong preventive and therapeutic efficacy against CVA10 infection. 
In addition, our structural and functional studies show that NAb 
2G8 cross-reacts with three forms of capsids and binds at a border 
region spanning all three viral proteins, VP1 to VP3. The atomic 
details revealed for the CVA10 antigenic sites and NAb 2G8 can 
inform vaccine and therapeutic design.
RESULTS
CVA10 mature virion as a viable vaccine candidate
The CVA10 strain CVA10-FJ-01 (GenBank accession no. KY012321) 
was cultivated in human rhabdomyosarcoma (RD) cells. Three types 
of particles, corresponding to the bottom, middle, and top bands, 
were isolated and purified by centrifugation, polyethylene glycol 
(PEG) precipitation, ultracentrifugation, and ultrafiltration. SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) showed that the 
particles in the bottom band (lane 1) are composed of four capsid 
proteins, VP1 to VP4 (Fig. 1A). These particles contain RNA ge-
nome, which are verified with a 260/280 absorbance ratio of 1.76 
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and with electron microscopy (EM) images of negative-stained 
samples (Fig. 1A) and vitrified specimens (fig. S1A). In contrast, the 
middle (lane 2) and top (lane 3) bands show no trace of VP4 in gel 
electrophoresis (Fig.  1A) and give 260/280 absorbance ratios of 
1.54 and 0.76, respectively, and the negative staining and cryo-EM 
further confirmed the presence of RNA in the middle band but its 
absence in the top band (Fig. 1A and fig. S1, B and C). In addition, 
the release of RNA and stability of particles were explored with the 
particle stability thermal release assay (PaSTRy). A significant ex-
posure of RNA occurred at ~25°C in the particles of the middle 
band versus at ~55°C in those of the bottom band, which indicates 
that the former is less stable than the latter (Fig. 1B). Together, these 
characteristics suggest that the bottom, middle, and top bands cor-
respond to mature virions, A-particles, and procapsids, respectively.
The immunogenicity of CVA10 was investigated by vaccinating 
mice separately with purified mature virions, heat-inactivated (HI) 
mature virions, A-particles, HI A-particles, or procapsids. Antisera 
harvested from all treated mice at 2-week intervals were tested with 
an in vitro neutralization assay. Antisera collected from all experi-
mental groups show high and comparable average neutralization 
titers (Fig. 1C). In particular, mature virions exhibited about 13-fold 
higher titer than the other groups at week 8, indicating that mature 
virions are the most immunogenic and can elicit the highest NAb 
titer. In addition, the in vivo protective efficacy of antisera against 
CVA10 infection was evaluated using the neonatal mouse model (26). 
Antisera from all groups of immunized mice showed 100% treat-
ment efficacy, but the mice in control groups started to show signs 
of illness at 4 days post-infection (d.p.i.) and all died within 7 d.p.i. 
Fig. 1. Stability and immunogenicity of CVA10 particles. (A) The SDS-PAGE analysis and negative staining EM of the three types of CVA10 particles. Lane 1, mature 
virions; lane 2, A-particles; lane 3, procapsids; and lane 4, molecular mass (MM) markers (in kilodaltons). Protein components of each type of particles are labeled along 
the right side of each lane. The genome is present in both mature virions and A-particles but absent in procapsids. (B) The genome exposure and thermal stability of 
CVA10 particles determined by PaSTRy. The high fluorescence value throughout the whole temperature range indicates that the genome in the A-particle is more ex-
posed than the one in the mature virion. (C) In vitro neutralizing titer of antisera of CVA10 particles. BALB/c mice were vaccinated intraperitoneally with CVA10 mature 
virions, HI mature virions, A-particles, HI A-particles, procapsids, and adjuvant (control) at weeks 0 and 3. Mice were bled at weeks 0, 2, 4, 6, and 8 for neutralization assays, 
and the levels of neutralizing titers of antisera are expressed as means ± SD. Statistical significance is determined by Mann-Whitney test (**P < 0.01). (D) In vivo protective 
efficacy of antisera of CVA10 particles. The infected mice were treated with antisera and were monitored daily for clinical illness and death. All experimental groups 
showed 100% survival rates, but 0% for two control groups.
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(Fig. 1D). Therefore, in terms of strong antigenicity and potent ther-
apeutic efficacy of antisera, all three types of particles, particularly 
the mature virions, could serve as promising vaccine candidates 
against CVA10 infection.
Characterization of anti-CVA10 NAb 2G8
A monoclonal antibody (mAb) against CVA10, named 2G8, which 
exhibits high neutralizing activity in the neutralization assay in vitro 
[median inhibitory concentration (IC50) = 0.2 g/ml] (Fig. 2A), was 
selected for subsequent characterization. 2G8 exhibits high binding 
efficiency with CVA10 virions, A-particles, or procapsids in enzyme- 
linked immunosorbent assay (ELISA) tests (Fig. 2B). In addition, 
murine CVA10 antisera and CVA10-positive human antisera were 
subjected to a competitive binding efficiency test against 2G8. Both 
sera show high blocking rates against 2G8 binding to CVA10 par-
ticles ranging between 65.0 and 92.4% (Fig. 2C).
The in vivo preventive and therapeutic efficacies of 2G8 were 
evaluated in neonatal mice challenged with CVA10. NAb 2G8 (dose = 
30 g/g) was administered either before or after mice were chal-
lenged with CVA10 viruses [dosage = 107 median tissue culture in-
fectious dose (TCID50)]. The mice in the control group started to show 
signs of illness at 4 d.p.i. and all died within 8 d.p.i.; in contrast, all 
of the animals in both preventive and therapeutic groups survived 
(Fig. 2D).
Whether NAb 2G8 neutralizes the CVA10 virus in its pre- or 
post-attachment step during infection was tested by mixing NAb 
2G8 with the CVA10 virus either before or 1 hour after the addition 
of host cells. The neutralizing potency of 2G8 in the pre-attachment 
assay was about 10 times higher than that in the post-attachment 
assay (Fig. 2E). As further demonstrated in the cell-based reverse 
transcription polymerase chain reaction (RT-PCR) assay, the num-
ber of virus particles attached to host cells was inversely correlated 
with the input concentration of 2G8 (Fig. 2F). Hence, 2G8 mani-
fests higher inhibitory capacity in pre-attachment as opposed to 
post- attachment virus cell binding.
Comparisons of CVA10 mature virion, A-particle, and 
procapsid structures
Each of the particles corresponding to the three bands separated by 
ultracentrifugation was vitrified and imaged by low-dose cryo-EM 
methods (fig. S1, A to C), and the acquired images were subjected to 
single-particle analysis with the program RELION. As revealed by 
two-dimensional (2D) and 3D classification results, ~30% of the 
particles in the bottom band were mature virions and the remaining 
~70% were A-particles (fig. S1, F and G). These purified particles 
were stored at 4°C before vitrification, which indicates that CVA10 
mature virions can transform into A-particles in the absence of 
treatments with low pH or heat. The subsequent 3D reconstruc-
tions of the mature virion, A-particle (bottom band), A-particle* 
(middle band), and procapsid yielded final density maps with 
estimated resolutions of 3.4, 3.4, 3.6, and 4.0 Å, respectively (Fig. 3, 
A to C; figs. S2, A and B, and S3; and Table 1). The mature virion 
map reveals a pseudo T = 3 icosahedral capsid structure with a max-
imum diameter of ~315 Å along the fivefold axis (Fig.  3A). The 
A-particle maps are essentially identical with a correlation coeffi-
cient of 0.97 (fig. S2C), and hence, to simplify further analysis, the 
map of A-particle from the bottom band (3.4 Å) was the subject 
of subsequent studies. The A-particle and procapsid also share an 
essentially identical, expanded capsid structure (correlation coeffi-
cient, 0.95), with a larger diameter of ~330 Å than that of the ma-
ture virion (Fig. 3, B and C). Both expanded particles show open 
channels at the icosahedral twofold axes (Fig.  3, B and C). In 
addition, the encapsidated RNA genome is present in the mature 
virion and A-particle but absent in the procapsid (fig. S4, A to C).
The three density maps at near-atomic resolution allowed us to 
build atomic models of each of the three particle types (Table 1). 
The mature virion contains densities attributable to all four capsid 
proteins (VP1 to VP4), whereas the A-particle and procapsid lack 
identifiable density corresponding to VP4 (table S1). As in the case 
of CVA6 (17), the existence of VP0 (that is, the precursor of VP2 
and VP4) in the procapsid particle was verified by gel electrophoresis 
(Fig. 1A), but the density of the VP0 sequence corresponding to 
VP4 was unidentifiable in the near-atomic resolution cryo-EM 
map. Superposition of asymmetric units (protomers) of atomic 
models verifies the similar capsid structures of the A-particle and 
procapsid [overall root mean square deviation (RMSD) = 0.57 Å 
in C atoms; table S2]. However, the mature virion differs signifi-
cantly from the A-particle (RMSD = 1.12 Å in C atoms between 
protomers; table S2). The differences are mostly located at the VP1 
N terminus and in the surface loops (BC, DE, HI, and GH) close to 
the icosahedral fivefold axes, and the RMSD value for C atoms in 
VP1 is 1.52 Å (Fig. 3, D and E, and table S2). In addition, the VP3 
BC loop of the mature virion is shifted slightly compared with that 
of the A-particle or procapsid (Fig. 3F). These surface loops, partic-
ularly the VP1 loops, have been shown to be the critical antigenic 
epitopes in many picornaviruses, such as EV71 (27), CVA6 (17), 
foot and mouth disease virus (28), and HRV (29). Hence, the dif-
ferences of antigenic determinants among three types of particles 
explain why the mature virion of CVA10 confers different immuno-
genicity from the other two.
Structure comparisons between the CVA10 mature virion 
and other enteroviruses
The overall structure of the CVA10 mature virion is similar to the 
virions of other representative enteroviruses [EV71 (22), CVA16 
(30), CVB3 (31), poliovirus (32), and EVD68 (33)] (Fig. 3G and fig. S5), 
and the RMSD values range from 0.79 to 1.73 Å between C atoms 
in a protomer (table S2). The CVA10 mature virion closely resem-
bles CVA16 (RMSD = 0.79 Å) and EV71 (RMSD = 0.90 Å), both of 
which belong to EV-A. This similarity includes the hydrophobic 
pockets (Fig. 3H) and even the embedded pocket factors (Fig. 3I), 
which play a critical role in initiating the viral uncoating process 
(22). However, the pocket regions are recognizably different when 
CVA10 is compared with CVB3 (species B), poliovirus (species C), or 
EVD68 (species D) (Fig. 3, H and I). A similar case occurs at the 
“canyon” regions as well, which usually offer the binding sites for 
host receptor(s) and primarily comprise VP1 BC and GH loops and 
the VP2 EF loop (fig. S6A). Overall, the canyon conformation of 
CVA10 is similar to that of EV71 and CVA16, but different from 
those of non–species A enteroviruses (fig. S6, B to F). The VP2 EF 
loop of the CVA10 mature virion slightly extends inward, leading to 
a narrower distal part of the canyon (fig. S6). In addition, the VP1 
GH loop (the south part of the canyon) of CVA10 extends further 
to form the front part of the canyon, which is flatter than that 
observed in CVB3, poliovirus, and EVD68 (fig. S6, D to F). Notably, 
because density attributed to the VP1 BC loop is smeared in the cryo-
EM density map of the CVA10 mature virion, the BC loop was 
excluded from the atomic model.
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Fig. 2. Characterizations of NAb 2G8. (A) Neutralization assay of CVA10 NAb 2G8. The IC50 value is 0.2 g/ml. (B) Binding efficacy of NAb 2G8 evaluated with the indirect 
ELISA. NAb 2G8 exhibits high binding affinities with the CVA10 particles [median effective concentration (EC50) values from 83.1 to 251.1 ng/ml]. The IC50 and EC50 values 
were calculated with nonlinear regression fitting curves. The optical density (OD) value  was read at A450/620. (C) The competitive ELISA of NAb 2G8. The binding of NAb 
2G8 to CVA10 particles was significantly blocked by sera from mice immunized with CVA10 and CVA10-positive human sera. The percentages of blocking are expressed 
as means ± SD. (D) In vivo preventive and therapeutic efficacy of NAb 2G8. The infected mice were treated with NAb 2G8 12 hours before (blue line) or 24 hours after (red 
line) infection intraperitoneally with CVA10 and monitored daily after inoculation. Both experimental groups showed 100% survival rates, but 0% for two control groups. 
(E) Neutralization assay of NAb 2G8 at pre-attachment (blue line) or post-attachment (red line). NAb 2G8 exhibits much higher neutralizing capacity at pre-attachment 
(IC50 = 2.1 g/ml) than at post-attachment (IC50 = 22.7 g/ml). (F) Amount of cell-bound CVA10 viruses detected by RT-PCR. Indicated with the relative CVA10 genome 
level, the amount of cell-bound viruses gradually decreased as a function of increasing NAb 2G8 concentrations in both cases of pre- and post-attachment. Values are 
expressed as means ± SD. Experiments were repeated in triplicate. PBS, phosphate-buffered saline.
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Fig. 3. Atomic structures of the CVA10 mature virion, A-particle, and procapsid. (A to C) The isocontoured display of cryo-EM density maps (radially colored) of ma-
ture virion (A), A-particle (B), and procapsid (C) viewed along a twofold axis. One icosahedral asymmetric unit and icosahedral axes are labeled with a white triangle and 
numbers. (D to F) Superpositions (a protomer) of the CVA10 mature virion (red), A-particle (blue), and procapsid (cyan). The differences are mainly located at the VP1 
N-termini (D), the VP1 loops (BC, DE, HI and GH) close to fivefold axes (E), and the VP3 BC loop (F). (G) Superpositions (a protomer) of mature virions of CVA10 (red), EV71 
(orange), CVA16 (magenta), CVB3 (yellow), poliovirus (gray), and EVD68 (green). (H) Cutaway view of all the pocket factors (represented with sticks) in (G) situated in a 
“pocket” (light blue) of the CVA10 mature virion. (I) Back view of (H) without the pocket density. The CVA10 mature virion resembles CVA16 and EV71 much more than it 
does CVB3, poliovirus, and EVD68.
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The capsid structure of the CVA10 A-particle was also similar to 
that of EV71, CVA16, and CVA6 with RMSD values (C atoms in a 
protomer) of 1.03, 0.85, and 0.62 Å, respectively (table S2). The super-
position of four structures reveals that the biggest differences are 
located at some surface loops of VP1 (BC, DE, EF, and HI) and VP3 
(AB and BC). In particular, the VP1 BC loop of the CVA10 A-particle 
extends further toward the fivefold vertex of the capsid compared to 
that of EV71, CVA16, and CVA6 (fig. S2, D to F, and table S2).
Cryo-EM reconstructions of CVA10 particles complexed  
with 2G8
To investigate the molecular determinants of 2G8, we obtained three 
cryo-EM structures of Fab 2G8 in complex with the CVA10 mature 
virion (CVA10-M-2G8), A-particle (CVA10-A-2G8), and procapsid 
(CVA10-P-2G8). The acquired micrographs and subsequent 2D clas-
sification of extracted particle images clearly exhibit the presence of 
extra density features at high radii (fig. S1, D and E). These features 
Table 1. Statistics of 3D reconstructions and model refinements. RMS, root mean square. 
Mature virion 
(CVA10-M)
A-particle 
(CVA10-A)
A-particle* 
(CVA10-A*)
Procapsid 
(CVA10-P) CVA10-M-2G8 CVA10-A-2G8 CVA1-P-2G8
Data collection
Microscope Titan Krios Titan Krios Tecnai F30 Tecnai F30 Tecnai F30 Tecnai F30 Tecnai F30
Voltage (kV) 300 300 300 300 300 300 300
Detector K2 K2 Falcon II Falcon II Falcon II Falcon II Falcon II
Pixel size (Å) 1.36 1.36 1.128 1.128 1.128 1.128 1.128
Electron dose (Å2) 60 60 25 25 25 25 25
Frames 60 60 17 17 17 17 17
Defocus range 
(m)
0.5–4.7 0.5–4.7 0.6–4.3 0.7–4.4 0.4–5.9 0.4–5.9 0.5–5.7
Reconstruction
Software RELION 2.0
Number of used 
micrographs
1792 1792 532 543 1749 1749 1809
Number of used 
particles
17,092 66,306 9411 21,158 36,555 14,425 24,764
Final resolution 
(Å)
3.4 3.4 3.6 4.0 3.9 4.3 4.2
Average B factor 
(Å2)
−153.0 −177.9 −206.9 −271.7 −244.0 −253.0 −276.7
Model building
Software Coot
Refinement
Software Phenix
Model statistics
Correlation 
coefficient 
(around atoms)
0.8495 0.8544 — 0.8685 0.8607 0.8601 0.8685
No. of protein 
atoms
6304 5083 — 4827 8082 5094 4994
Ramachandran 
outliers
0.00% 0.00% — 0.00% 0.00% 0.00% 0.00%
Ramachandran 
favored
93.27% 92.15% — 89.7% 87.99% 90.72% 90.18%
Rotamer outliers 0.00% 0.18% — 0.00% 0.00% 0.00% 0.00%
C deviations 0 0 — 0 0 0 0
Clashscore 2.73 2.49 — 4.71 4.84 2.98 5.78
RMS (bonds) 0.0078 0.0052 — 0.0089 0.0123 0.0077 0.0089
RMS (angles) 1.2 1.2 — 1.3 1.3 1.2 1.3
EMRinger score 4.7 4.1 — 4.1 3.3 3.8 2.8
*A-particle from the middle band.
 o
n
 Septem
ber 25, 2018
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Zhu et al., Sci. Adv. 2018; 4 : eaat7459     19 September 2018
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 13
presumed to represent the Fabs had density levels comparable to 
those of capsid, which suggests that Fab 2G8 bound at near-saturation 
level. The following 3D image reconstructions yielded density maps 
with final estimated resolution limits of 3.9 Å (CVA10-M-2G8), 
4.3 Å (CVA10-A-2G8), and 4.2 Å (CVA10-P-2G8) (Table 1 and 
fig. S3). The density maps reveal the same epitope and binding pat-
tern (60 copies of 2G8 per particle) in all three immune complexes 
(Fig. 4A and figs. S4, D to F, and S7, A to C). The epitope of 2G8 
maps to the south rim of the canyon surrounding the quasi- threefold 
axis, where all three capsid proteins (VP1 to VP3) converge (Fig. 4, 
B and C).
The cryo-EM density map of CVA10-M-2G8 at near-atomic res-
olution allowed us to build an atomic model of the capsid and the 
bound variable domain of the Fab. This model reveals that the Fab- 
capsid interaction interface projects a footprint across three viral 
proteins (VP1 to VP3) and buries a total surface area of ~1100 Å2 on 
the capsid (Fig. 4C and fig. S7D). Such interface establishes an elab-
orate network of interactions including 14 hydrogen bonds and nine 
salt bridges between complementarity-determining regions (CDRs) 
and the capsid (Fig. 4, D to G, and table S3). All three CDRs in the 
heavy chain (HCDRs) of the Fab variable domain interact with the 
capsid at the VP1 C termini, VP2 EF loop, and VP3 AB loop (Fig. 4, 
D to G, and table S3). In contrast, only one CDR in the light chain 
(LCDR) interacts with the VP1 C termini.
The lower resolution limits of CVA10-A-2G8 and CVA10-P-2G8 
density maps meant that only atomic models of the capsids in these 
immune complexes were successfully built. The capsid structures in 
all three immune complexes are essentially identical to the struc-
tures of the corresponding unbound particles. These identities are 
confirmed with the overall RMSD values ranging from 0.42 to 0.86 Å 
between C atoms in one protomer (table S2). The twofold chan-
nels are still closed in CVA10-M-2G8 but remain open in both 
CVA10-A-2G8 and CVA10-P-2G8 (Fig. 5, A to C).
The capsid (protomer) of CVA10-A-2G8 or CVA10-P-2G8 was 
superimposed onto that of CVA10-M-2G8, which confirmed that 
the epitope of 2G8 is essentially identical across all three types of 
particles. Such identity is not accidental in the context of signifi-
cant differences located at  sheet jelly-roll folds of VP1 and VP3 
(Fig. 5D). The epitope of 2G8 sits near the quasi-threefold axis and 
represents a novel antigenic site (site 4) that barely overlaps any 
other previously reported neutralization epitopes (sites 1 to 3) of 
enteroviruses (Fig. 5E). 2G8 can cross-react with three distinct types 
of particles; thus, this epitope is a structurally well-conserved anti-
genic site during the life cycle of CVA10.
DISCUSSION
Picornaviruses primarily exist as two capsid forms in infected cells: 
empty procapsids (noninfectious) and mature virions (infectious) 
(22, 34). Upon binding with specific receptors, mature virions 
can transform into a transient form, uncoating intermediates or 
A-particles, which then become difficult to be isolated from the in-
fected cells (23, 35–37). However, as an anomalous member of the 
picornavirus family, CVA6 adopts procapsids and A-particles as 
stable beings in its life cycle (17). Here, the CVA10 procapsid, 
A-particle, and mature virion were routinely isolated, and a large 
fraction of the mature virions would transform into A-particles 
during long-term storage at 4°C. A recent study found that the VP1 
BC loop can regulate the assembly and maturation process of EV71 
particles and the subsequent conversion from mature virions to 
A-particles during viral uncoating and replication (38). Compari-
sons between CVA10 and other enteroviruses indeed revealed sig-
nificant variation in conformations at the VP1 BC loop (fig. S2F). 
Hence, the VP1 BC loop of CVA10 seems to play a key role in viral 
uncoating and capsid transition among different forms of particles.
In CVA16 and hepatitis A virus, the mature virions and procapsids 
were reported to have similar antigenicity, albeit their structures are 
distinct from each other (30, 34). As our results show, antisera elic-
ited from all three forms of CVA10 particles showed comparable 
neutralizing titers, together with the information of structurally de-
fined common epitope across three capsid forms, which indicates 
that all the particles share some structurally conserved epitopes, for 
instance, 2G8. Such epitope would be an excellent target for specific 
antiviral design against CVA10. On the other hand, CVA10 mature 
virions exhibit stronger antigenicity and more potent therapeutic 
efficacy than the other two types of particles. Comparisons between 
the atomic models of CVA10 particles revealed that the VP1 N ter-
mini loops close to fivefold axis and the VP3 BC loop probably de-
termine their respective antigenicity.
Previous cryo-EM studies of neutralizing mAb-virion complexes 
identified several neutralization antigenic sites in poliovirus, EV71, 
and CVA6, near the rims or the bottom of the canyon and the 
icosahedral three- or twofold axis (Fig. 5E) (17, 25, 27, 39–41). These 
neutralizing epitopes can be categorized into four major sites: site 1 
(EV71 MA28-7, poliovirus A12, and CVA6 1D5), site 2 (EV71 D5 
and 22A12), site 3 (EV71 E18), and site 4 (CVA10 2G8). Site 1 is 
located at the north rim of the canyon, which overlaps or is adjacent 
to the binding sites of the host cell receptors (17, 27, 39). Site 2 
mainly lies at the VP1 GH loop surrounding the twofold axis. It of-
fers either a monovalent or a bivalent binding pattern of the neu-
tralizing Fabs on EV71 mature virion and procapsid (40, 41). Site 3 
lies near the icosahedral threefold axis, and its elicited NAbs can trig-
ger the conversion from EV71 mature virions to A-particles, followed 
by a premature genome release (25). Here, our immune complex 
structures reveal that NAb 2G8 defines a novel capsid state cross- 
neutralization epitope, site 4, including the VP1 C termini, VP2 EF 
loop, and VP3 AB loop adjacent to the quasi-threefold channel on 
the CVA10 procapsid, mature virion, or A-particle. Researchers have 
reported a channel at the quasi-threefold axis and a larger opening 
at the twofold axis in the A-particles, either of which would allow 
the exit of the VP1 N termini, VP4, and viral RNA genome (22, 23). 
Therefore, NAb 2G8 may neutralize CVA10 particles in a manner 
that restricts the necessary conformational changes at the quasi- 
threefold channels that would otherwise lead to the release of the 
polypeptide chain and RNA genome.
Our study provides atomic-level information about molecular 
determinants of viral structure transitions, similar antigenicity, and 
conserved epitope, which are based on three capsid states of CVA10 
and immune complexes. Because NAb 2G8 can cross-react with 
all three forms of particles, its epitope can serve as a crucial tar-
get for vaccine design or NAb-based therapeutics against CVA10 
infection.
MATERIALS AND METHODS
Virus production and purification
The CVA10 strain CVA10-FJ-01 (GenBank accession no. KY012321) 
had been isolated from a clinical patient in 2014 in Fujian Province and 
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Fig. 4. Atomic structure of the CVA10 mature virion complexed with Fab 2G8. (A) The isocontoured display of the cryo-EM density map (radially colored) of the im-
mune complex CVA10-M-2G8 viewed along an icosahedral twofold axis. One icosahedral asymmetric unit and icosahedral axes are labeled with a white triangle and 
numbers. (B) A quarter of the central cross section of (A) exhibiting the densities of capsid (yellow to green) and Fab 2G8 (cyan to blue). The radii are marked by the arcs. 
(C) Surface representation of a protomer in (A) showing the interaction interface between Fab 2G8 (ribbon diagram) and the capsid. Only the variable domain (light chain, 
orange; heavy chain, magenta) of 2G8 is displayed. The capsid proteins VP1 to VP3 are colored light blue, light green, and light red, but the surface on the capsid covered 
by the footprint of the Fab 2G8 is respectively highlighted in their darker colors. (D to G) Expanded views of interaction interface spotlighting the VP1 C terminus (D and E), 
VP3 AB loop (F), and VP2 EF loop (G). Presumable hydrogen bonds and salt bridges in the interaction interface are marked by red dashed lines.
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was grown in RD cells (American Type Culture Collection, CCL-136) at 
a multiplicity of infection of 0.1. Infected cells were incubated at 37°C 
for 3 days and centrifuged at 7000g for 30 min to remove cell debris. The 
virus in the supernatant was precipitated using 6% (w/v) PEG 8000 in 
PBS buffer (pH 7.4). After one more centrifugation, the virus was resus-
pended in PBS buffer and subsequently loaded onto a 15 to 45% (w/v) 
sucrose density gradient for ultracentrifugation in a Beckman SW41 Ti 
rotor at 150,000g for 3.8 hours. The virus bands were individually col-
lected and dialyzed against PBS buffer. Then, the virus was concentrated 
with cutoff filters. All steps of the purification procedure were carried 
out at 4°C. The purity of virus preparation was assessed with Coomasie- 
stained SDS-PAGE gel (NuPAGE 4-12% Bis-Tris Gel, Invitrogen).
Fig. 5. Structure comparisons between three types of CVA10 particles complexed with Fab 2G8. (A to C) Views of the regions surrounding an icosahedral twofold 
axis of immune complex structures of CVA10-M-2G8 (A), CVA10-A-2G8 (B), and CVA10-P-2G8 (C). Two asymmetric units and icosahedral axes are labeled with two black 
triangles and numbers in (A). Capsid proteins are displayed in ribbon diagrams, while variable domains of Fab 2G8 are displayed in cryo-EM densities (gray). The atomic 
model of the variable domain is also shown in (A). (D) The superposition of capsid proteins of three immune complexes demonstrating the consistency of the epitope 
across three types of CVA10 particles. The atomic models of capsid proteins from CVA10-M-2G8 and variable domains of Fab 2G8 are shown in colored ribbons, but cap-
sid proteins of CVA10-A-2G8 and CVA10-P-2G8 are respectively shown in gray and white. (E) Reported epitopes of enteroviruses mapped onto the CVA10 density map 
showing only the surface region encircling an icosahedral fivefold axis. All these epitopes are classified into four antigenic sites (sites 1 to 4) surrounding two sides of the 
canyon. Site 1 represents epitopes in EV71 MA28-7 (yellow), CVA6 1D5 (orange), and poliovirus-A12 (lemon). Site 2 indicates the epitopes in EV71 D5 (blue) and EV71 
22A12 (marine). Site 3 belongs to the epitope in EV71 E18 (green). The epitope of 2G8 is uniquely located at site 4.
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Particle stability thermal release assay
ThermoFluor assay (42) was performed with an MX3005P RT-PCR 
instrument (Agilent/Stratagene). The presence of single-stranded RNA 
was detected with SYTO9 (Invitrogen) as a fluorescent probe. Each 
50-l reaction mixture, containing 1 g of virus and 5 M SYTO9 in 
PBS buffer, was set up in thin-walled PCR plates (Agilent). The flu-
orescence level was recorded in triplicate at temperatures between 
25° and 99°C at 0.5°C intervals.
Vaccine preparation and immunization of mice
The immunogenicity of the CVA10 virus was evaluated in BALB/c 
mice. The purified CVA10 mature virions and A-particles were in-
activated by heating at 56°C for 30 min. Viruses were diluted in PBS 
and mixed with an equal volume of aluminum adjuvant. Groups of 
mice (n = 5) were respectively vaccinated with mature virions, HI 
mature virions, A-particles, HI A-particles, procapsids, or aluminum 
adjuvant (control) at weeks 0 and 3. Each mouse was intraperitone-
ally injected with 0.5 ml of the samples at 2.5 g per dose. Antisera 
elicited from all groups were inactivated by incubation at 56°C for 
30 min and stored at −20°C. All animal experiments were approved 
by the Institutional Animal Care and Use Committee and Laboratory 
Animal Management Ethics Committee at Xiamen University.
Preparation of antibodies and antibody fragments
To obtain the anti-CVA10 mAb 2G8, BALB/c mice were immu-
nized subcutaneously with CVA10 mature virions emulsified in an 
equal volume of Freund’s adjuvant (Sigma-Aldrich) and boosted twice 
at 2-week intervals. After the final boost, spleen cells from immu-
nized mice were fused with Sp2/0 myeloma cells, and the obtained 
hybridoma supernatants were screened by indirect ELISA and neu-
tralization assay against CVA10. Antibody 2G8 was purified from 
mouse ascetic fluid produced from single-positive cells by protein A 
chromatography (GE Healthcare). To prepare the Fab fragment, 
mAb 2G8 was digested at 37°C for 12 hours with papain at 1% (per 
mil) (w/w) in PBS buffer, containing 0.01 M l-cysteine and 0.05 M 
EDTA. The digestion was terminated with the addition of 0.03 M 
iodoacetamide. Fab fragments were then purified with a DEAE col-
umn (Tosoh). The variable domains of both heavy and light chains 
were sequenced by PCR amplification.
In vitro neutralization assay
RD cells were preseeded in 96-well plates with 1 × 104 cells per well. 
Antisera or mAb 2G8 was serially diluted twofold and incubated 
with an equal volume of CVA10 (100 TCID50 per well) at 37°C for 
1 hour. The mixtures were then added to cells and incubated at 37°C 
for 5 to 7 days. The cytopathic effect (CPE) was observed with 
microscopy, and a neutralizing titer was defined as the highest dilu-
tion giving >50% neutralization of the well. A neutralizing titer 
of antisera with values of ≥1:8 was considered as a threshold for 
positivity.
ELISA
Binding ELISA
The purified CVA10 full particles (mature virions:A-particles ≈ 3:7), 
A-particles, and procapsids were respectively diluted in PBS buffer 
and coated onto 96-well ELISA plates with 50 ng of viruses per well. 
After overnight incubation at 4°C, the plates were washed once with 
PBST buffer (0.05% Tween 20 in PBS buffer) and saturated with the 
saturation buffer (0.25% casein and 1% gelatin in PBS buffer) at 
37°C for 2 hours. mAb 2G8 at various concentrations was then added 
to the plates, followed by incubation at 37°C for 1 hour. After five 
washes with PBST buffer, the plates were mixed with horseradish 
peroxidase– conjugated goat anti-mouse (GAM-HRP; 1:5000 dilu-
tion) immunoglobulin G antibody and incubated at 37°C for 30 min. 
After five more washes, the plates were incubated with a solution of 
tetramethylbenzidine for 15 min, and the reaction was terminated 
with 2.1 M H2SO4. Thereafter, the absorption was measured at 
A450/620.
Competitive ELISA
The antisera from mice immunized with CVA10 or CVA10-positive 
human sera were used for the competitive ELISA. mAb 2G8 was 
conjugated to HRP using the NaIO4 oxidation method. The HRP-
2G8 (1:3000 dilution) was used to block the binding of sera (1:100 
dilution) to CVA10 coated on ELISA plates. Percentage inhibition 
(PI) was calculated with the following formula: PI (%) = 100 − 
[(ODsample/ODcontrol) × 100].
In vivo protection assay
In prevention experiments, groups of neonatal mice were inoculated 
intraperitoneally with 100 l of either antisera or NAb 2G8 (30 g 
for each gram of body weight) 12 hours before intraperitoneal inoc-
ulation with 100 l of CVA10 (106 TCID50 per mouse). In treatment 
experiments, mice were simply inoculated intraperitoneally with 
NAb 2G8 24 hours after inoculation of CVA10. The mice in the con-
trol groups were treated with PBS buffer via the same route. Every 
group comprised 8 to 10 mice. All mice were monitored daily for 
clinical illness and death until 20 d.p.i.
Pre- and post-attachment neutralization assays
RD cells were preseeded in 96-well plates and ready for two assays. 
Each incubation in both assays was performed at 4°C with a duration 
of 1 hour unless otherwise stated. In the pre-attachment neutral-
ization assay, serially diluted mAb 2G8 was incubated with CVA10 
and then added to the cells for one more incubation. In the post- 
attachment neutralization assay, the cells were first incubated with 
CVA10 and then washed twice with cold PBS buffer. Different dilu-
tions of mAb 2G8 were subsequently added for one more incuba-
tion. The cells were finally washed twice with cold PBS buffer and 
incubated at 37°C for 4 days. The CPE was observed under the 
microscope.
RT-PCR to quantitate virus on cell surface
The amount of CVA10 particles remaining on the surface of RD 
cells was estimated by a one-step, quantitative RT-PCR as previously 
described (17). Some steps of the experimental procedure are simi-
lar to the pre- and post-attachment neutralization assay described 
in the above section. Briefly, CVA10 was mixed with different con-
centrations of mAb 2G8 either before or after the viruses were coated 
on preseeded cells. The mixture was then incubated at 4°C for 1 hour. 
After three washes with cold PBS buffer, total RNA was isolated 
using the QIAamp Mini Viral RNA Extraction Kit (Qiagen). RT-PCR 
reaction was performed with the CFX96 Real-Time PCR Detection 
System (Bio-Rad). Gene-specific primers (forward, 5′-TACTTTG-
GGTGTCCGTGTTT-3′; reverse, 5′-TGGCCAATCCAATAGC-
TATATG-3′; probe, 5′-FAM- AYTGGCTGCTTATGGTGA-
CRAT-BHQ1-3′) were used for the RT-PCR experiment. The relative 
levels of CVA10 RNA in different samples were estimated by the 
comparative 2−Ct method (43).
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Negative staining EM
Purified CVA10 viruses were diluted in PBS buffer and then ab-
sorbed onto 200-mesh carbon-coated copper grids for 1 min. The 
grids were washed twice with double-distilled water and subse-
quently negatively stained with 2% phosphotungstic acid (pH 6.4) 
for 30 s. Specimens were evaluated and imaged with the FEI Tecnai 
T12 transmission electron microscope at a magnification of 25,000×.
Cryo-EM sample preparation and data acquisition
Three types of CVA10 particles (mature virion, A-particle, and pro-
capsid) were purified and stored at 4°C for cryo-EM sample prepara-
tion. The CVA10 immune complexes were prepared by mixing Fab 
2G8 with CVA10 particles at a molar ratio of 72:1. Mixtures were 
then incubated at 37°C for 30 min. Aliquots (3 l) of samples of 
different viral particles or immune complexes were applied onto glow- 
discharged holey carbon Quantifoil Cu grids (R2/2, 200 mesh, Quan-
tifoil Micro Tools) inside the FEI Mark IV Vitrobot at a humidity 
level of 100%, blotted with filter papers for 6 s, and then plunged into 
liquid ethane cooled by liquid nitrogen. The vitrified specimens were 
examined under low-dose conditions at 300 kV with the FEI Titan 
Krios or Tecnai F30. Micrographs acquired with the Krios were 
recorded on the post-GIF K2 camera at a nominal magnification of 
105,000×, corresponding to a calibrated physical pixel size of 1.36 Å 
(0.68 Å for super-resolution pixel size). The slit width in the Gatan 
GIF system was set to 20 eV to remove inelastically scattered elec-
trons. Each movie contains 60 subframes with a total exposure time 
of 12 s (0.2 s for each subframe); the dose rate was set to ~9.5 e− 
per physical pixel per second; hence, the total dose of each exposure 
was ~60 e−/Å2. Micrographs acquired with the Tecnai F30 were 
recorded on the Falcon II direct electron detector in the 17-frame 
movie mode at a nominal magnification of 93,000×, corresponding to 
a pixel size of 1.128 Å. The total electron dose was set to 25 e−/Å2, and 
the total exposure time was 1 s. Micrographs with minimum drift or 
astigmatism were selected for subsequent image processing.
Image processing
Movie frames were aligned to correct the drift and beam-induced 
motion with the program MotionCor2 (44), and the contrast trans-
fer function of each aligned micrograph was estimated with the pro-
gram Gctf (45). Particles from several representative micrographs 
were manually boxed using the e2boxer.py program from the EMAN 
2.1 package (46), which were then used as reference for autopicking 
particles of whole data set with the program RELION 2.0 (47). All 
extracted particle images underwent multiple rounds of 2D classifi-
cations, and the classes that exhibited identifiable secondary struc-
tures features were rated as “good” ones. Particles in good classes 
were used to generate initial 3D models with the random model 
method in the program AUTO3DEM (48) and were further pro-
cessed for 3D image reconstructions with the program RELION 2.0. 
The resolutions of maps were estimated using gold-standard crite-
ria with the Fourier shell correlation (FSC) cutoff = 0.143 (49). Local 
resolution variations were estimated using the program ResMap (50).
Model building and refinement
The initial atomic model templates of all three particles and immune 
complexes were generated from homology modeling upon CVA6 
[Protein Data Bank (PDB) code: 5XS4 (17)] and its immune com-
plex [PDB code: 5XS7 (17)] by Accelrys Discovery Studio software 
(51). Then, the template was docked into a segmented volume 
(enclosing a promoter) of final cryo-EM maps (viral particles or im-
mune complexes) using Chimera (52). The sequence assignment was 
guided by the clearly recognizable features for bulky side chains, such 
as Phe, Tyr, Arg, and Trp. The manual model building and auto matic 
refinement were alternately and iteratively performed in Coot (53) 
and the module phenix.real_space_refine in PHENIX (53, 54). The 
refined protomer was docked into the density of six neighboring 
protomers, which were then treated as a whole model for further 
optimization to avoid clashes between protomers. Model statistics 
including bond lengths, bond angles, all atom clashes, rotamer sta-
tistics, Ramachandran plot statistics, etc., were closely inspected with 
Coot during the whole process. The final models were validated using 
Molprobity (55) and EMRinger (56). Multiple sequence alignments 
were performed using ClustalW and ClustalX (version 2) on the 
EBI server, and the results were generated using ESPript (57). Fig-
ures were prepared with Chimera (52) and PyMOL (58). The roadmap 
of Fabs footprint was displayed with the program Radial Interpretation 
of Viral Electron density Maps (RIVEM) (59). The interactions be-
tween virus capsid and Fab were inspected with the software CCP4 (60) 
and the PISA sever (www.ebi.ac.uk/pdbe/pisa). The intermolecular 
interactions were analyzed on the basis of the assumption that cut-
off distances are 4 Å for a hydrogen bond and 3.5 Å for a salt bridge.
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